Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

Metal-organic frameworks (MOFs) and method of using the MOFs to catalyze reactions involving epoxide ring-opening mechanisms are provided. The structure of the MOFs can be represented by the formula: M.sub.6(μ.sub.3-ligand).sub.8(OH.sub.x).sub.8(TBAPy).sub.2, where M is Zr or Hf, the ligands are selected from hydroxo-, oxo- and aquo-ligands, and x is independently selected from 1 or 2.

Metal-organic frameworks (MOFs) and method of using the MOFs to catalyze reactions involving epoxide ring-opening mechanisms are provided. The structure of the MOFs can be represented by the formula: M.sub.6(μ.sub.3-ligand).sub.8(OH.sub.x).sub.8(TBAPy).sub.2, where M is Zr or Hf, the ligands are selected from hydroxo-, oxo- and aquo-ligands, and x is independently selected from 1 or 2.

Provided herein are novel compounds (e.g., Formula I), pharmaceutical compositions, and methods of using related to GPR40. The compounds herein are typically GPR40 agonists, which can be used for treating a variety of disorders, conditions or diseases such as Type 2 diabetes.

##STR00001##

Metal-organic frameworks (MOFs) having inorganic nodes that comprise an octahedral Hf.sub.6 cluster capped by eight .sub.3-ligands and having twelve octahedral edges, wherein the .sub.3-ligands are hydroxo ligands, oxo ligands or aquo ligands; and organic linkers connecting the organic nodes, the organic linkers comprising 1,3,6,8-tetrakis(p-benzoic acid)pyrene units; wherein eight of the twelve octahedral edges of the inorganic nodes are connected to the 1,3,6,8-tetrakis(p-benzoic acid)pyrene units are provided.

Metal-organic frameworks (MOFs) having inorganic nodes that comprise an octahedral Hf.sub.6 cluster capped by eight .sub.3-ligands and having twelve octahedral edges, wherein the .sub.3-ligands are hydroxo ligands, oxo ligands or aquo ligands; and organic linkers connecting the organic nodes, the organic linkers comprising 1,3,6,8-tetrakis(p-benzoic acid)pyrene units; wherein eight of the twelve octahedral edges of the inorganic nodes are connected to the 1,3,6,8-tetrakis(p-benzoic acid)pyrene units are provided.

Metal-organic frameworks (MOFs) having inorganic nodes that comprise an octahedral Hf.sub.6 cluster capped by eight .sub.3-ligands and having twelve octahedral edges, wherein the .sub.3-ligands are hydroxo ligands, oxo ligands or aquo ligands; and organic linkers connecting the organic nodes, the organic linkers comprising 1,3,6,8-tetrakis(p-benzoic acid)pyrene units; wherein eight of the twelve octahedral edges of the inorganic nodes are connected to the 1,3,6,8-tetrakis(p-benzoic acid)pyrene units are provided.

Metal-organic frameworks (MOFs) having inorganic nodes that comprise an octahedral Hf.sub.6 cluster capped by eight .sub.3-ligands and having twelve octahedral edges, wherein the .sub.3-ligands are hydroxo ligands, oxo ligands or aquo ligands; and organic linkers connecting the organic nodes, the organic linkers comprising 1,3,6,8-tetrakis(p-benzoic acid)pyrene units; wherein eight of the twelve octahedral edges of the inorganic nodes are connected to the 1,3,6,8-tetrakis(p-benzoic acid)pyrene units are provided.

Metal-organic frameworks (MOFs) and method of using the MOFs to catalyze reactions involving epoxide ring-opening mechanisms are provided. The structure of the MOFs can be represented by the formula: M.sub.6(.sub.3-ligand).sub.8(OH.sub.x).sub.8(TBAPy).sub.2, where M is Zr or Hf, the ligands are selected from hydroxo-, oxo- and aquo-ligands, and x is independently selected from 1 or 2.